Hot News
Anpac Biologics officially enters global medical equipment sales: it has received orders and down payments of approximately 10 million yuan from Southeast Asia
Anpac Biomedical Technology Co., Ltd. ("Anpac Bio"), a company engaged in early detection of cancer, recently announced that it had received the first payment from a Malaysian customer at the end of February 2023. Biotech has previously signed an equipment purchase contract for the purchase
Anpac Biotechnology and the Clinical Research Center of Shanghai Jiao Tong University School of Medicine jointly published research results on multi-year multi-cancer detection and follow-up of the general public.
Anpac Biomedical Technology Co., Ltd. (hereinafter referred to as "Anpac Bio") is a biotechnology company listed on Nasdaq that engages in early detection of cancer. Anpac Biotech has two qualified medical laboratories in China. A 2021 market research report by Frost & Sullivan, an authoritative
Anpac Biotechnology, the advocate of multi-cancer screening technology, won the “Leading Enterprise” Award at the 2022ZAODX World Early Cancer Screening Conference
From July 15 to 17, 2022, the ZAODX World Early Cancer Screening Conference, focusing on the research and development and transformation and application of global early screening cutting-edge technologies, was successfully held in Guangzhou. The conference focused on the three major perspectives of "world pattern",
Anpac Biotechnology published clinical trials and results of CDA technology for lung cancer efficacy evaluation at the American Association for Cancer Research annual meeting.
Abstract: The academic paper "Clinical Experiments and Results of the Application of Innovative Biophysics-based CDA Technology in Efficacy Evaluation of Lung Cancer" written by Anpac Biotech in collaboration with the School of Life Sciences of Fudan University and Shanghai Changhai Hospital was approved by the
Anpac Bio’s new cancer early screening technology has been verified and can provide early warning of more than 20 types of cancer risks
Shangguan News Report: All cancer categories have relatively high specificity, above 95%, indicating that this blood testing technology is suitable for cancer screening in the general population. Recently, the Clinical Research Center of Shanghai Jiao Tong University School of Medicine and Anpac Biotech, together with
